Employees: 1,388
Size Ind-Swift Laboratories (INDSWFTLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $314M, the 1045th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹336.75 on 18 Nov 2026.
Performance Over six months the shares gained 149.9%, against -22.6% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 66.4% over the last twelve months (peer median +2.3%); the operating margin is 9.4% (peer median -7.0%).
Valuation It trades at 3.4× enterprise value to sales against a peer median of 4.8× (9th cheapest of 19).
Capital Return on invested capital runs 7.7 points below its cost of capital (12.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹7.53B | ₹6.28B | ₹5.64B | ₹17.1B | ₹12.1B |
| Revenue growth | — | +11% | -67% | +42% | — |
| Gross profit | ₹2.57B | ₹1.12B | ₹837M | ₹4.06B | ₹2.57B |
| EBITDA | ₹1.03B | ₹284M | -₹155M | ₹3.07B | ₹2.31B |
| Net income | ₹836M | ₹431M | ₹2.50B | ₹5.39B | ₹476M |
| Free cash flow | n/a | -₹1.06B | -₹965M | -₹5.07B | ₹573M |
| Capital expenditure | n/a | ₹877M | ₹644M | ₹730M | ₹128M |
| Total debt | ₹214M | ₹179M | ₹330M | ₹2.06B | ₹8.53B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INDSWFTLAB.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.3% | -9.4% | 8th highest of 21 |
| 6-month return | +149.9% | -22.6% | 2nd highest of 21 |
| Distance from 52-week high | -21.1% | -40.5% | 4th highest of 21 |
| Revenue growth (TTM) | +66.4% | +2.3% | 2nd highest of 19 |
| Operating margin | 9.4% | -7.0% | 4th highest of 19 |
| EV / Sales | 3.4× | 4.8× | 9th cheapest of 19 |
| ROIC minus cost of capital | -7.7 pp | -7.1 pp | 9th lowest of 18 |
| EV / EBITDA | 25.0× | 9.6× | 2nd most expensive of 6 |
| Net debt / EBITDA | -3.5× | -1.2× | 2nd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $314M | +150% | +66% | 9% | 3.4× | n/a | n/a |
| Chengdu Huasun Technology 000790.SZ | China | $312M | -20% | -36% | -57% | 5.6× | 27.5% | -6.4% |
| Inovio Pharmaceuticals INO | United States | $317M | +37% | +64% | -25,954% | 921.6× | n/a | n/a |
| Kitazato 368A.T | Japan | $317M | +7% | +9% | 52% | 3.1× | -16.8% | +5.4% |
| Alembic ALEMBICLTD.NS | India | $309M | +25% | -5% | 26% | 13.0× | 44.3% | +26.7% |
| Enwei Pharmaceutical 301331.SZ | China | $308M | -20% | -7% | 5% | 2.1× | 14.0% | +7.3% |
| Atea Pharmaceuticals AVIR | United States | $320M | -5% | n/a | n/a | n/a | n/a | n/a |
| GC Corp. 005250.KS | South Korea | $321M | -45% | +2% | 3% | 1.1× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $321M | -24% | +3% | 7% | 1.8× | 6.1% | +62.1% |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $322M | -12% | +6% | -104% | 21.4× | n/a | n/a |
| Hinova Pharmaceuticals 688302.SS | China | $305M | -35% | +251% | -195% | 17.1× | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $305M | -60% | n/a | n/a | n/a | n/a | n/a |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $326M | -39% | +10% | -8% | 6.2× | n/a | n/a |
| Chongqing Hifuture Information Technology 002168.SZ | China | $326M | -27% | +2% | -6% | 7.4× | 14.3% | -14.0% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | -1% | +5% | 22% | 1.8× | -11.5% | +10.3% |
| Honz Pharmaceutical 300086.SZ | China | $299M | -40% | -23% | -54% | 7.3× | 56.0% | -12.8% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $297M | -30% | -3% | 7% | 2.3× | 4.6% | -0.3% |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $296M | -21% | -32% | -58% | 4.8× | 1.4% | -4.9% |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $333M | -28% | +3% | 6% | 1.4× | 9.2% | +6.5% |
| Mayne Pharma MYX.AX | Australia | $333M | +155% | -6% | -14% | 1.2× | 19.0% | -0.9% |
| BioDlink International 1875.HK | Hong Kong | $334M | -24% | -51% | -31% | 4.8× | n/a | n/a |